# M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

> **NCT06177041** · PHASE3 · RECRUITING · sponsor: **FutureGen Biopharmaceutical (Beijing) Co., Ltd** · enrollment: 486 (estimated)

## Conditions studied

- Locally Advanced Unresectable or Metastatic Gastric Cancer
- Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** M108 monoclonal antibody
- **DRUG:** Placebo
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06177041
- **Lead sponsor:** FutureGen Biopharmaceutical (Beijing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-25
- **Primary completion:** 2027-01-11
- **Final completion:** 2027-04-11
- **Target enrollment:** 486 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06177041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06177041, "M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06177041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*